LUCD Stock Forecast: Lucid Diagnostics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Lucid Diagnostics, Inc. is $3. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 36 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Lucid Diagnostics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (80): Reported profit is backed by cash, and the company is not expanding recklessly.
Value (6): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
LUCD stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on LUCD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Nov 2026 | BTIG | Reiterates | Buy | $2.50 |
| 23 Oct 2026 | BTIG | Reiterates | Buy | $2.50 |
| 27 Aug 2026 | Ascendiant Capital | Maintains | Buy | $9.25 → $9.50 |
| 17 Aug 2026 | BTIG | Reiterates | Buy | $2.50 |
| 8 June 2026 | Ascendiant Capital | Maintains | Buy | $9.00 → $9.25 |
| 15 May 2026 | BTIG | Reiterates | Buy | — |
| 15 May 2026 | Maxim Group | Maintains | Buy | — |
| 9 Apr 2026 | Ascendiant Capital | Maintains | Buy | — |
| 30 Mar 2026 | BTIG | Reiterates | Buy | — |
| 26 Mar 2026 | Needham | Reiterates | Buy | — |
| 10 Dec 2025 | Ascendiant Capital | Maintains | Buy | — |
| 13 Nov 2025 | Needham | Reiterates | Buy | — |
| 6 Oct 2025 | Ascendiant Capital | Maintains | Buy | — |
| 10 Sept 2025 | BTIG | Reiterates | Buy | — |
| 5 Sept 2025 | BTIG | Maintains | Buy | — |
| 13 Aug 2025 | Needham | Reiterates | Buy | — |
| 16 July 2025 | Needham | Reiterates | Buy | — |
| 6 June 2025 | Ascendiant Capital | Maintains | Buy | — |
| 15 May 2025 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 14 May 2025 | Needham | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for LUCD.
This page is one stock. Monday covers all of them.
LUCD appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
LUCD vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Lucid Diagnostics, Inc. returned −63.5% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
LUCD analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 13.3×
- Price / book
- 12.0×
- EV / EBITDA
- —
Cheaper than 10% of US stocks
Cheaper than 6% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 2.0%
- Operating margin
- —
- Net margin
- —
Higher than 5% of US stocks
- Return on equity
- −305.6%
- Return on assets
- −79.0%
- Dividend yield
- —
Higher than 5% of US stocks
Higher than 4% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Lucid Diagnostics, Inc. has a market value of $72.6M and an enterprise value of $72.0M.
Revenue in the twelve months to 30 June 2026: $5.4M. The latest quarter grew 26.7% year on year.
Net income over the same four quarters: −$52.3M, a −959.8% net margin.
Diluted earnings per share, trailing twelve months: −$0.45.
Free cash flow in the twelve months to 30 June 2026: −$47.2M.
Lucid Diagnostics, Inc. employs 82 people — $66K of revenue per employee.
Data provided by Twelve Data
LUCD and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at LUCD’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Lucid Diagnostics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about LUCD
What is the LUCD stock price forecast for 2026-2027?
The median 12-month analyst price target for Lucid Diagnostics, Inc. is $3, with estimates ranging from $2 to $9.5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is LUCD stock a buy right now?
Of the 4 analysts covering Lucid Diagnostics, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lucid Diagnostics, Inc. 36 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank LUCD?
As at 21 Nov 2026, Lucid Diagnostics, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (80 of 100).
Will LUCD stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts is $3, and Ticker Nerd's factor model ranks Lucid Diagnostics, Inc. 36 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the LUCD stock forecast for 2030?
No analyst covering Lucid Diagnostics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LUCD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $9.5 over the next 12 months.
How has LUCD stock performed over the past year?
Lucid Diagnostics, Inc. returned -63.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Lucid Diagnostics, Inc. do?
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on the early detection of esophageal precancer and cancer in patients with gastroesophageal reflux disease, or GERD. Its core offering centers on the EsoGuard Esophageal DNA Test, which is performed using samples collected with the EsoCheck Esophageal Cell Collection Device to help identify at-risk patients before disease progresses.
About Lucid Diagnostics, Inc.
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on the early detection of esophageal precancer and cancer in patients with gastroesophageal reflux disease, or GERD. Its core offering centers on the EsoGuard Esophageal DNA Test, which is performed using samples collected with the EsoCheck Esophageal Cell Collection Device to help identify at-risk patients before disease progresses. The company’s products are designed for use in clinical settings and support physicians in screening patients who may benefit from further evaluation. Lucid Diagnostics serves the healthcare market by addressing an important unmet need in cancer prevention and risk assessment, particularly for a condition linked to highly lethal esophageal adenocarcinoma. The company is headquartered in New York, New York, and operates as a subsidiary of PAVmed Inc.
CEO Dr. Lishan Aklog M.D. · 82 employees · United States · https://www.luciddx.com